ArticleBMC infectious diseases2026
Syndromic surveillance and immunoprofiling of inbound travelers as a proxy for national SARS-CoV-2 trends in Uganda: implications for border health policy in resource-limited settings.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated SARS-CoV-2 infection rates among inbound international travelers to Uganda between May 2022 and July 2024, following the introduction of mandatory COVID-19 vaccination in March 2021. It also explored the relationship between traveler positivity rates and national COVID-19 trends.
methodsWe analyzed laboratory records of 4,517 inbound travelers tested at a laboratory which screens travelers at Entebbe International Airport. The testing algorithm included nucleic acid amplification testing (NAAT) for viral detection and chemiluminescent immunoassays to measure IgG antibody titers. Infection rates were stratified by vaccination status and age. To understand how vaccine- or infection-induced immunity might wane differently across age groups, impacting infection risk, we examined the interaction between IgG levels and age on PCR positivity and compared traveler positivity trends to national case data.
resultsThe overall infection rate was 10.2% (461/4,517), with unvaccinated travelers having a significantly higher infection rate (13.1%; 253/1,935) than vaccinated ones (8.1%; 208/2,582). After adjusting for age and sex in a multivariate logistic regression analysis, vaccinated individuals had 42% lower odds of testing positive compared to those who were unvaccinated (Adjusted Odds Ratio: 0.58; 95% CI: 0.48–0.71; p < 0.001). Protective IgG antibodies were present in 93.4% (2,412/2,582) of vaccinated individuals, compared to 6.1% (118/1,935) of the unvaccinated. PCR positivity was influenced by both age and IgG levels, with a non-linear interaction. Traveler positivity remained high across the study period, even as national case counts declined post-August 2022.
conclusionVaccination significantly reduced infection risk and conferred higher IgG protection among travelers. The consistent high positivity among travelers, despite low national transmission, underscores the importance of continued surveillance at ports of entry as an early warning system, especially during global variant emergence. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.